Stay updated on Pembrolizumab in Lymphoma Subtypes Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Lymphoma Subtypes Clinical Trial page.

Latest updates to the Pembrolizumab in Lymphoma Subtypes Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoChange DetectedA new revision, v3.5.0, has been added; the previous revision, v3.4.3, has been removed.SummaryDifference0.0%

- Check17 days agoChange DetectedThe page now displays Revision: v3.4.3 and no longer shows Revision: v3.4.2.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check46 days agoChange DetectedPage updated to Revision: v3.4.2. The previous funding-status notice (v3.4.1) and related operating-status messaging have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check53 days agoChange DetectedAdded a government funding lapse notice and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check60 days agoChange DetectedGlossary display added; QC-related field labels and FEAR Act labeling adjusted; page revision tag updated to v3.4.0.SummaryDifference0.2%

- Check74 days agoChange DetectedPage revision updated to v3.3.4 (replacing v3.3.3); this appears to be a minor site update with no changes to study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Lymphoma Subtypes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Lymphoma Subtypes Clinical Trial page.